Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v13-EN | Version v4-FR | |
---|---|---|
Language | English | French |
Date Updated | 2023-07-04 | 2022-10-04 |
Drug Identification Number | 02474921 | 02474921 |
Brand name | PROBUPHINE | PROBUPHINE |
Common or Proper name | Buprenorphine hydrochloride implant | Buprenorphine hydrochloride implant |
Company Name | KNIGHT THERAPEUTICS INC. | KNIGHT THERAPEUTICS INC. |
Ingredients | BUPRENORPHINE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE |
Strength(s) | 80MG | 80MG |
Dosage form(s) | IMPLANT | IMPLANT |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | Implant kit has 4 individually pouched Probuphine implants. | Implant kit has 4 individually pouched Probuphine implants. |
ATC code | N07BC | N07BC |
ATC description | ||
Reason for discontinuation | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated discontinuation date | 2023-05-30 | 2023-05-30 |
Actual discontinuation date | 2023-07-03 | |
Remaining supply date | 2023-05-30 | |
Discontinuation status | Discontinued | To be discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | We regret to announce that following inventory depletion, this product will be officially discontinued and will no longer be marketed in Canada. The reason for discontinuation is due to the inability to successfully acquire continued supply and is unrelated to any safety concerns. | Our current inventory of Probuphine (80 mg buprenorphine hydrochloride implant) is anticipated to deplete by May 2023. We regret to announce that following inventory depletion, this product will be officially discontinued and will no longer be marketed in Canada. The reason for discontinuation is due to the inability to successfully acquire continued supply and is unrelated to any safety concerns. |
Health Canada comments |